Absorbable Stent Linked to Increase in Cardiac Events — Physician’s First Watch

Medical News |
March 20, 2017

Absorbable Stent Linked to Increase in Cardiac Events

By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

The Absorb GT1 Bioresorbable Vascular Scaffold is associated with an increased rate of major adverse cardiovascular events, the FDA warned on Saturday. The fully absorbable stent system was approved in July 2016.

The agency's review of data from the ABSORB III trial found that, over 2 years, major adverse cardiovascular events occurred in 11% of patients treated with the everolimus-eluting Absorb GT1 scaffold versus 8% of those treated with a metallic everolimus-eluting stent. In addition, the rate of stent thrombosis was more than twice as high with the Absorb GT1 scaffold (1.9% vs. 0.8%). Adverse events were more common in small heart vessels.

The FDA is conducting additional safety analyses with the Absorb GT1's maker.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.